Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Thermo Fisher Scientific Inc. (NYSE:TMO ) Q2 2023 Earnings Conference Call July 26, 2023 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President and Chief Executive Officer Stephen Williamson - Senior Vice President and Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Dan Arias - Stifel Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Derik De Bruin - Bank of America Securities Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2023 Second Quarter Conference Call. My name is Ellen, and I'll be coordinating the call for today.

Thermo Fisher Scientific Inc. (TMO) Q2 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Thermo Fisher (TMO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Shares of Thermo Fisher Scientific (NYSE:TMO) fell Wednesday morning after the medical equipment manufacturer slashed its annual profit forecast.  The company dropped its full-year earnings projection to between $22.28 and $22.72 per share, compared to its previous forecast of $23.70.

Thermo Fisher stock slumps on depressed profit forecast

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.15 per share, missing the Zacks Consensus Estimate of $5.43 per share. This compares to earnings of $5.51 per share a year ago.

Thermo Fisher Scientific (TMO) Lags Q2 Earnings and Revenue Estimates

Thermo Fisher Scientific Inc. TMO, -0.11% shares fell more than 5% premarket on Wednesday after the medical device and lab equipment maker trimmed its full-year earnings and revenue guidance. “The macroeconomic environment became more challenging in the second quarter,” CEO Marc Casper said in a statement, as economic activity in China slowed and businesses across the economy became more cautious in their spending.

Thermo Fisher stock drops after company trims full-year outlook

Medical equipment maker Thermo Fisher Scientific on Wednesday cut its annual profit forecast, hurt by weak demand for its biopharma services including tools and compounds used to make therapeutics and vaccines.

Thermo Fisher cuts 2023 forecast as biotech funding woes linger

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023. Second Quarter 2023 Highlights Second quarter revenue was $10.69 billion, 3% lower versus the same quarter last year. Core organic revenue growth was 2%. Second quarter GAAP diluted earnings per share (EPS) was $3.51. Second quarter adjusted EPS was $5.15. The macroeconomic environment was more challengin.

Thermo Fisher Scientific Reports Second Quarter 2023 Results

YONKERS, N.Y.--(BUSINESS WIRE)--CYBRA Corporation, the New York-based developers of Edgefinity IoT® tracking software, announced the release of their latest case study highlighting the strategic value of an RFID-based tracking solution for the health and sciences industry. Thermo Fisher required a foolproof inventory control system that would track the processing and transport of serum, which is kept in quarantine at sub-zero temperatures that require meticulous monitoring. Thermo Fisher needed.

Thermo Fisher Relies on CYBRA's RFID Tracking and Alerting Capabilities to Keep Blood Cold

Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.

What's in Store for Thermo Fisher (TMO) in Q2 Earnings?

CARLSBAD, Calif.--(BUSINESS WIRE)--To extend the benefits of genomic testing research for reproductive health labs, Thermo Fisher Scientific today launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research. The Ion ReproSeq PGT-A Kit* and the Ion AmpliSeq Polyploidy Kit* mark the first research use reproductive health assays avail.

Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research

Abbott Labs

Elevance Health Inc

Home Depot

Intercontinental Exchange

Tractor Supply

Toro

UnitedHealth Group

Visa

The article presents a monthly series of 10 top-ranked dividend growth stocks for further research and potential investment. The stocks are ranked based on quality scores, with tie-breaking metrics including dividend safety scores, credit ratings, and forward dividend yield. The top three stocks for this month are Visa, UnitedHealth, and Intercontinental Exchange. The article also provides key metrics and fair value estimates for each stock, and suggests that Tractor Supply Company passes all selection criteria for adding new positions to the author's DivGro portfolio.

10 Dividend Growth Stocks For July 2023

Thermo Fisher's (TMO) Diomni Enterprise Software effortlessly connects each individual processing stage to a single, integrated platform.

Thermo Fisher (TMO) Launches Diomni Enterprise Software

Franklin Resources

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Jenny Johnson, president and chief executive officer of Franklin Resources, Inc. (NYSE:BEN), has been elected to its board of directors. The appointment brings the total number of Thermo Fisher board members to 12. In a career at Franklin Templeton spanning 35 years, Johnson has been a key driver in the company's transformation to what is now one of the largest global.

Thermo Fisher Scientific Elects New Director to Board

Laboratories increasingly need the specialized instruments and services that Thermo Fisher provides.

Why Thermo Fisher Is More Than a Pandemic Play

CARLSBAD, Calif.--(BUSINESS WIRE)--To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results. By connecting workflow steps within one interface, Diomni Enterprise can increase a lab's ability to dynamically respond to today's rapidly changing testing environment. The solution can be used by a variety of labs per.

Thermo Fisher Scientific Launches Scalable Diomni Enterprise Software for Molecular Diagnostics Labs and Test Developers

Thermo-Fisher is among the top leaders in the life sciences segment with a demonstrated positive track record. The company combines internal development, acquisitions and opportunistic tactics to maintain its profile. I believe that shares are currently undervalued.

Thermo Fisher: Why I'm Betting On This Life Sciences Kingpin

Thermo Fisher's (TMO) acquisition of CorEvitas is likely to strengthen its value proposition.

Thermo Fisher (TMO) Announces the Acquisition of CorEvitas

Thermo Fisher is a great life science giant which is battling tough comparables with pandemic-related revenues on their retreat. I like the historical achievements, but with growth being flattish, valuations are full (given where interest rates are). I like the business in the long haul, but would like to see a $4 handle before initiating a position.

Thermo Fisher Scientific: Continuing To Add To The Fortress

Thermo Fisher Scientific (NYSE:TMO) Inc on Thursday announced it would acquire data intelligence company CorEvitas from Audax Private Equity for $912.5 million in cash. CorEvitas is a provider of data and analytics to pharmaceutical and biotech companies and expects revenue of $110 million in 2023, Reuters reported.

Thermo Fisher Scientific to acquire data intelligence provider CorEvitas

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Audax Private Equity (“Audax”), a leading alternative investment manager and capital partner for North American middle market companies, announced today it has entered into a definitive agreement to sell CorEvitas, LLC (“CorEvitas”), a leading provider of real-world evidence for regulatory approved medical treatments and therapies, to Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”). The transaction is expected to be completed by the end of 20.

Audax Private Equity Announces Agreement to Sell CorEvitas to Thermo Fisher Scientific

Thermo Fisher Scientific Inc. TMO said Thursday it agreed to pay $912.5 million in cash for Waltham, Mass.-based CorEvitas LLC, a provider of “regulatory-grade” evidence for approved medical treatments and therapies, from seller Audax Private Equity.

Thermo Fisher buying CorEvitas for $912.5 mln

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definitive agreement to acquire CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash. Real-world evidence is the collection and use of patient health outcomes data gathered through r.

Thermo Fisher Scientific to Acquire CorEvitas

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2023 before the market opens on Wednesday, July 26, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The.

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 26, 2023

Thermo Fisher Scientific is a leading healthcare supplier with strong customer relationships and a track record of impressive revenue and net income growth. TMO's superior business model, focused on innovation and serving scientific customers, positions it for long-term growth and outperformance in the healthcare sector. Despite a challenging first quarter, TMO maintains a confident outlook, and its valuation, although not cheap, is justified by expectations of double-digit annual earnings growth.

News for Thermo Fisher Scientific Stock (TMO)